AKEBIA THERAPEUTICS, INC. Inventory, Finished Goods, Net of Reserves
AKEBIA THERAPEUTICS, INC. (AKBA) had Inventory, Finished Goods, Net of Reserves of $14.32 million as of 2024-06-30, per its 10-Q filed 2024-08-08.
Discontinued › Notes › Inventory › Inventory, Finished Goods and Work in Process, Net of Reserves
us-gaap:InventoryFinishedGoodsNetOfReserves · last filed 2024-08-08
- 2024-06-30: Inventory, Finished Goods, Net of Reserves $14.32M.
- 2024-03-31: Inventory, Finished Goods, Net of Reserves $11.40M.
- 2023-12-31: Inventory, Finished Goods, Net of Reserves $11.39M.
- 2023-09-30: Inventory, Finished Goods, Net of Reserves $15.80M.
| Period end | Inventory, Finished Goods, Net of Reserves |
|---|---|
| 2024-06-30 | $14.32M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $11.40M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $11.39M 10-Q · filed 2024-08-08 |
| 2023-09-30 | $15.80M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $12.33M 10-Q · filed 2023-08-28 |
| 2023-03-31 | $12.50M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $13.68M 10-K · filed 2024-03-14 |
| 2022-09-30 | $18.97M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $18.84M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $8.21M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $14.66M 10-K/A · filed 2023-08-28 |
| 2021-09-30 | $16.18M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $16.72M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $6.52M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $19.69M 10-K · filed 2022-03-01 |
| 2020-09-30 | $27.52M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $38.64M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $36.92M 10-Q · filed 2020-05-05 |
| 2019-12-31 | $42.10M 10-K · filed 2021-02-25 |
| 2019-09-30 | $45.86M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $30.21M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $27.90M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $18.18M 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |